Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 31;25(21):5063.
doi: 10.3390/molecules25215063.

p-Cymene Complexes of Ruthenium(II) as Antitumor Agents

María Angeles Pujante-Galián  1 , Sergio A Pérez  2 , Mercedes G Montalbán  2 , Guzmán Carissimi  2 , Marta G Fuster  2 , Gloria Víllora  2 , Gabriel García  1
Affiliations

p-Cymene Complexes of Ruthenium(II) as Antitumor Agents

María Angeles Pujante-Galián et al. Molecules. .

Abstract

In this work, the cytotoxic behavior of six ruthenium(II) complexes of stoichiometry [(η6-p-cymene)RuCl2L] (I-VI), L = 4-cyanopyridine (I), 2-aminophenol (II), 4-aminophenol (III), pyridazine (IV), and [(η6-p-cymene)RuClL2]PF6; L = cyanopyridine (V), L = 2-aminophenol(VI) towards three cell lines was studied. Two of them, HeLa and MCF-7, are human carcinogenic cells from cervical carcinoma and human breast cancer, respectively. A comparison with healthy cells was carried out with BGM cells which are monkey epithelial cells of renal origin. The behavior of complex II exhibits selectivity towards healthy cells, which is a promising feature for use in cancer treatment since it might reduce the side effects of most current therapies.

Keywords: MTT assay; anticancer activity; complexes; cytotoxicity; ruthenium.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

Figures

Scheme 1
Scheme 1
Complexes [η6-(biphenyl)Ru(en)Cl]PF6 [17,18,19,20,21] and [(η6-p-cymene)Ru(pta)Cl2] [22,23].
Scheme 2
Scheme 2
Complexes [(η6-p-cymene)Ru(CN)X]0/+ (X=Cl, py or 4-NMe2py) containing a cyclometalated 2-ppy or 1-ppz with a non-coordinated CHO [24].
Scheme 3
Scheme 3
Scheme of reactions.
Figure 1
Figure 1
Dose–response curves of HeLa, MCF-7 and BGM cells treated with complexes II (a), VI (b) and III (c) for 48 h.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dabrowiak J.C. Metals in Medicine. 2nd ed. John Wiley & Sons Ltd.; Hoboken, NJ, USA: 2017. pp. 91–216.
    1. Facchetti G., Rimoldi I. Anticancer platinum(ii) complexes bearing N-heterocycle rings. Bioorg. Med. Chem. Lett. 2019;29:1257–1263. doi: 10.1016/j.bmcl.2019.03.045. - DOI - PubMed
    1. Zaki M., Hairat S., Aazam E.S. Scope of organometallic compounds based on transition metal-arene systems as anticancer agents: Starting from the classical paradigm to targeting multiple strategies. RSC Adv. 2019;9:3239–3278. doi: 10.1039/C8RA07926A. - DOI - PMC - PubMed
    1. Abid M., Shamsi F., Azam A. Ruthenium Complexes: An Emerging Ground to the Development of Metallopharmaceuticals for Cancer Therapy. Mini-Rev. Med. Chem. 2016;16:772–786. doi: 10.2174/1389557515666151001142012. - DOI - PubMed
    1. Schmid W.F., John R.O., Arion V.B., Jakupec M.A., Keppler B.K. Highly Antiproliferative Ruthenium(II) and Osmium(II) Arene Complexes with Paullone-Derived Ligands. Organometallics. 2007;26:6643–6652. doi: 10.1021/om700813c. - DOI

LinkOut - more resources